Navigation Links
Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial
Date:11/20/2011

Treatment with dexpramipexole a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine. Some preliminary results of the study were presented at the 2009 International Symposium on ALS/MND and the 2010 American Academy of Neurology annual meeting.

"Today there are only two FDA-approved drugs used to treat ALS riluzole, which extends life about 10 percent, and Nuedexta, which treats the emotional instability that characterizes ALS and other neurological disorders," says Merit Cudkowicz, MD, director of the Massachusetts General Hospital (MGH) Neurology Clinical Trials Unit and ALS Center, lead author of the study. "We need more therapies to slow, halt and ultimately reverse the course of disease and also therapies to treat the symptoms."

Also known as Lou Gehrig's disease, ALS is a progressive neurodegenerative disease affecting motor neurons in the brain and spinal cord. Death of these nerve cells stops the transmission of neural impulses to muscle fibers, leading to weakness, paralysis and usually death from respiratory failure. Mitochondrial dysfunction is among several factors believed to underlie nerve cell death. Initially developed by Knopp Biosciences of Pittsburgh, dexpramipexole appears to protect neurons from mitochondrial dysfunction.

Several investigators from Knopp, which sponsored the study reported in the current article, collaborated with Cudkowicz and the Northeast ALS Consortium on the trial. Co-founded and co-directed by Cudkowicz, the Northeast ALS Consortium includes over 100 clinical sites throughout North America that work collaboratively on clinical trials and has established the infrastructure necessarily to quickly and efficiently bring forward new treatments for people with the disorder.

The progression of ALS can vary widely, with some patients surviving decades after diagnosis and others dying within a year. Therefore it can be quite challenging to develop phase 2 trials, which need both to test dosage levels and to determine potential effectiveness in small groups of participants over brief periods of time. To meet this challenge, the research team devised a two-stage study. In the first, 102 patients who had recently been diagnosed with ALS were randomized into four groups, receiving oral tablets of either a placebo or dexpramipexole at total daily dosages of either 50, 150 or 300 mg for 12 weeks. When that stage was completed, participants continuing in the trial received placebo only for four weeks and then were re-randomized into two different groups, receiving daily dosages of either 50 or 300 mg of the study drug for 24 weeks.

Results of the first stage showed that receiving dexpramipexole appeared to slow the progression of symptoms measured both by the ALS Functional Rating Scale and by pulmonary capacity. The protective effect was greatest in the 300 mg group in whom symptom progression was approximately 30 percent slower than in the placebo group and little effect was seen in those receiving 50 mg. The second stage had similar results, with slower disease progression and a reduced risk of death in participants receiving the higher dosage. While results were not generally statistically significant, due to the small size and short duration of the study, all data trends were dose responsive.

"Since individual participants could have been in different treatment groups in the first and second stages of the study, seeing the same dose-dependent differences at both stages gives us confidence in the data. In a way, this was two supportive studies in one trial design," says Cudkowicz. "Confirmation of these findings in the phase 3 clinical trial, which is currently ongoing, would give us even more confidence in this study design for phase 2 testing in ALS. We hope that adding this drug to the approved treatments for ALS would give patients a chance to stay healthier longer, with slower decline of function and increased survival." Cudkowicz is the Julieanne Dorn Professor of Neurology at Harvard Medical School.


'/>"/>

Contact: Mike Morrison
mdmorrison@partners.org
617-724-6425
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish to ... advantage of a cosmetic procedure known as Carbon Dioxide (C02) Fractional Laser ... of age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity or ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... will speak at the American Conference Institute’s 21st Drug & Medical Device Litigation ... Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than 100 business, civic, ... to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This inaugural event, ... and operating support to UNCF-member institutions, including Miles College, Oakwood University, Tuskegee University, ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 2016  Results from the Phase II SUSTAIN study ... reduced the median annual rate of sickle cell-related pain ... 2.98, p=0.010) in patients with or without hydroxyurea therapy ... being featured in the official press briefing at the ... Meeting and presented during the Plenary Scientific Session tomorrow ...
(Date:12/2/2016)... December 2, 2016 - bioLytical lanza el INSTI HIV ... la OMS     Continue Reading ... ... , , bioLytical ... anunciado hoy que está expandiendo el lanzamiento de su INSTI HIV Self Test ...
(Date:12/2/2016)... December 2, 2016 According to the ... Market Study on Automated Endoscope Reprocessors: Single Basin Automated Endoscope ... 8.6% Between 2016 and 2024 " the global automated endoscope reprocessors market was ... to expand at a CAGR of 7.2% during an eight-year ... 1,367.6 Mn by 2024. ...
Breaking Medicine Technology: